Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04101422 · ClinicalTrials.gov registry record · NA
Utilizing Augmented Reality as an Adjunct for Smoking Cessation
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 197
- Enrollment target
NCT04101422: Completed NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT04101422 is a NA study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 197 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04101422, a NA study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 197 participants
- Enrollment target
Study Summary
The purpose of the study is to develop an preliminary test a tobacco smoking-related augmented reality (AR) paradigm for eventual development as an adjunctive tobacco cessation intervention.
Primary Outcome
Participants will rate their urge to smoke on a 10-point Likert scale from 1 (absolutely no urge to smoke) to 10 (strongest urge to smoke).
Interventions
- BEHAVIORAL Augmented Reality 1
- BEHAVIORAL Augmented Reality 2
- BEHAVIORAL Augmented Reality 3
- BEHAVIORAL Augmented Reality 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2019-10-07 |
| Est. Completion | 2022-02-14 |
| Phase | NA |
What the finished NCT04101422 record still lists
NCT04101422 is an interventional study that assigns participants to a tested intervention. The registered 197 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 4 interventions - of which Augmented Reality 1 is the first listed.
NCT04101422 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04101422 about?
NCT04101422 is a clinical study titled "Utilizing Augmented Reality as an Adjunct for Smoking Cessation". The purpose of the study is to develop an preliminary test a tobacco smoking-related augmented reality (AR) paradigm for eventual development as an adjunctive tobacco cessation intervention.
What is the current status of trial NCT04101422?
This trial is currently completed. It is a NA study. The enrollment target is 197 participants. The study started on 2019-10-07. Estimated completion is 2022-02-14.
What interventions are being tested in trial NCT04101422?
The interventions under investigation include: Augmented Reality 1 (BEHAVIORAL), Augmented Reality 2 (BEHAVIORAL), Augmented Reality 3 (BEHAVIORAL), Augmented Reality 4 (BEHAVIORAL).
Who is sponsoring clinical trial NCT04101422?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04101422's enrollment target sits among peer trials
197 567th of 2000 higher than 1,434 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04219254 · 197 participants · Phase 1
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- NCT06173778 · 197 participants · Phase 2
Semaglutide for Post-Smoking Cessation Weight Management
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI